Squarepoint Ops LLC Vertex Pharmaceuticals Inc Call Options Transaction History

Squarepoint Ops LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $1.33 Million - $1.47 Million	2,900 Added 30.21%	12,500 $5.81 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $667,777 - $825,401	1,700 Added 21.52%	9,600 $4.5 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $693,073 - $758,336	-1,700 Reduced 17.71%	7,900 $3.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $2.81 Million - $3.37 Million	8,200 Added 585.71%	9,600 $3.91 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $220,094 - $246,337	700 Added 100.0%	1,400 $492,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $198,261 - $226,170	700 New	700 $220,000
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $1.34 Million - $1.67 Million	5,700 New	5,700 $1.61 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.